Nima Farzan, Kinnate CEO
August 26, 2020 07:30 AM EDTUpdated 08:55 AM
Financing

Kin­nate gets $98M Se­ries C to push pre­ci­sion on­col­o­gy drugs to the clin­ic

Nicole DeFeudis

Editor

Less than a year af­ter bank­ing $74.5 mil­lion in a Se­ries B, San Diego-based Kin­nate Bio­phar­ma is fol­low­ing up with a Se­ries C to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

A service from the Financial Times